Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health an
about
Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis CPegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis CPegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis CChronic hepatitis C virus infection and lipoprotein metabolismHCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortalityThe current economic burden of cirrhosis.Current status and future directions in the management of chronic hepatitis C.Chronic hepatitis C virus (HCV) disease burden and cost in the United States.Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument.Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic Hepatitis C.Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination.Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population.The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.Viral hepatitis: Cost-effectiveness of direct-acting antivirals for chronic hepatitis C.Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice.Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha.Potential epidemiologic, economic, and budgetary impacts of current rates of hepatitis C treatment in medicare and non-medicare populations.
P2860
Q24200189-300525DA-B251-4111-AD4E-698643002FA3Q24240315-49B7CE4F-CF61-4D49-BACE-7FEBDC06C93CQ24241360-7670B220-F0FA-43B7-BB07-62FA0772A587Q26784234-59AD082C-A5D6-4A7E-9D67-2F75A1E132CEQ27488220-EC5A7D29-33B8-46FF-88EC-B066EC7C77C4Q35691411-74F8DC2F-6F9D-4BB0-B275-D8D2E6115D85Q35887719-877D26E7-A00F-4CBA-95F3-BD8FB6DA04CDQ37148328-C6B91500-4A31-4F51-82F3-A94FF77CD9D5Q38134312-7AB7787A-99EB-4C4A-9161-36AEBA1951F3Q40084155-F9841B5B-10DC-4E70-9ECB-BC6CE0006A7EQ40588090-A5EC7D03-8CF1-4A11-AF57-6F89F5F9C873Q40596218-3CE652CC-4733-40CF-B42F-FF04EFE32391Q41207230-E894610F-3562-40A4-AECA-09B97DFDED9BQ42988157-A5CABA5C-95AD-46AF-9109-74A7F69848BBQ42995272-DB5DB81F-9CB8-4AD0-BE02-90500B196101Q43685787-D42FE0ED-E1C2-4F73-B170-BC70F14E580DQ45811492-DE1DA78A-B0EA-45E8-AAC6-EEF76F253B65Q55163317-A5EB5273-3C01-420F-8E5E-DD9150D33611
P2860
Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health an
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Effectiveness and cost-effecti ...... Federal Ministry of Health an
@ast
Effectiveness and cost-effecti ...... Federal Ministry of Health an
@en
type
label
Effectiveness and cost-effecti ...... Federal Ministry of Health an
@ast
Effectiveness and cost-effecti ...... Federal Ministry of Health an
@en
prefLabel
Effectiveness and cost-effecti ...... Federal Ministry of Health an
@ast
Effectiveness and cost-effecti ...... Federal Ministry of Health an
@en
P2093
P2860
P1476
Effectiveness and cost-effecti ...... Federal Ministry of Health an
@en
P2093
Gaby Sroczynski
German Hepatitis C Model GEHMO Group
HTA Expert Panel on Hepatitis C
Uwe Siebert
P2860
P356
10.1017/S0266462305050075
P577
2005-01-01T00:00:00Z